Abstracts tagged "Insurance"

Abstract Number: 045 • 2020 Pediatric Rheumatology Symposium
No-Shows: a Search for Modifiable Risk Factors
Samantha Ong ¹, Xujia Li ¹ and Austin Dalrymple², ¹Saint Louis University School of Medicine, St. Louis, ²Saint Louis University School of Medicine, Saint Louis, Missouri
Background/Purpose: Missed ambulatory visits, or “no-shows,” limit patient access, increase costs, occupy provider time, and lead to worse patient outcomes. Only a few studies have…
Abstract Number: 2153 • 2018 ACR/ARHP Annual Meeting
The Effect of Socioeconomic Status on Treatment Outcomes in Lupus Nephritis: Private Versus Public Insurance
Arezoo Haghshenas¹, Phildrich Teh², Kristal Choi³, Abigail Benitez⁴, Lorena Salto³, Mathew Firek⁵, Karina Torralba⁶ and Vaneet K. Sandhu¹, ¹Division of Rheumatology, Loma Linda University, Loma Linda, CA, ²Internal Medicine, University of California, Riverside, Riverside, CA, ³Loma Linda University, Loma Linda, CA, ⁴Rheumatology, Loma Linda University, Loma Linda, CA, ⁵Riverside university health system, Moreno valley, CA, ⁶Loma Linda University Medical Center, Loma Linda, CA
Background/Purpose: Despite therapeutic advancements, lupus nephritis (LN) remains a major cause of mortality among patients with SLE. Loma Linda University Health serves a region in…
Abstract Number: 56 • 2015 ACR/ARHP Annual Meeting
Utilizing City-Wide Electronic Health Record Data to Assess Care Fragmentation in Patients with Systemic Lupus Erythematosus (SLE)
Kathryn Jackson, Theresa Walunas, Anh Chung and Rosalind Ramsey-Goldman, Northwestern University, Chicago, IL
Background/Purpose: Care fragmentation is associated with poor health outcomes and is hard to assess in a single-site data registry. The Chicago HealthLNK Data Repository (CHDR)…
Abstract Number: 457 • 2015 ACR/ARHP Annual Meeting
RA Patients with Medicare Only Insurance Have Similar Clinical Outcomes As Patients with Private Insurance Despite Having Less Access to Biologics
Marcia S. Genta¹, Amnon Sonnenberg² and Robert M. Genta³, ¹Dallas Arthritis Center, Dallas, TX, ²Medicine - Gastroenterology, Portland VAMC - Oregon Health & Science University, Portland, OR, ³Laboratory, Dallas Arthritis Center, Dallas, TX
Background/Purpose: We have previously shown that patients with Medicare only coverage without financial assistance from foundations were significantly less likely to receive Biologics than patients…
Abstract Number: 2444 • 2014 ACR/ARHP Annual Meeting
Pharmacist-Developed Letters May Enhance Success in Obtaining Insurer Approval for Off-Label Use of Biologics
Jessica F. Farrell^1,2,3, Lee S. Shapiro^1,2,4, Joel M. Kremer⁵ and Aixa Toledo-Garcia⁶, ¹Steffens Scleroderma Center, Saratoga Springs, NY, ²The Center for Rheumatology, Albany, NY, ³Pharmacy Practice, Albany College of Pharmacy & Health Sciences, Albany, NY, ⁴Albany Medical College, Albany, NY, ⁵Medicine, Albany Medical College and the Center for Rheumatology, Albany, NY, ⁶Rheumatology, The Center for Rheumatology, Albany, NY
Background/Purpose A growing number of publications suggest that biological DMARDs, predominantly approved for RA, can be efficacious treatment options for several rare rheumatic diseases. These potentially…
Abstract Number: 94 • 2014 ACR/ARHP Annual Meeting
Possible Effects of Medicare-Only Insurance Coverage on the Use of Biologics in Patients with RA
Marcia Genta, Dallas Arthritis Center, Dallas, TX
Background/Purpose: Biologics, a relatively new widely used class of medication that can substantially improve the course of RA, are expensive and their use is not…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].